ISPOR 2025

Join EVERSANA and global healthcare leaders as they convene at ISPOR 2025, the leading global conference for Health Economics and Outcomes Research (HEOR).

Our global Value & Evidence. Data & Analytics and Pricing and Market Access experts will be onsite to discuss how we use a variety of analytics, evidence generation, and evidence synthesis activities to help support market access and reimbursement for pharmaceutical and medical devices.

Schedule a meeting with one of our experts to discuss your business needs and visit us in Booth #701.

EVERSANA’s 2025 Oral and Poster Presentations

We are proud to present an oral presentation and several posters at this year’s ISPOR conference.

 Wednesday, May 14 – Poster Session 1 

• SA3: Methodologic Considerations to Guide Clinician Interpretation and Assessment of Network Meta-Analyses in Psoriasis
  Author(s):Kim A. Papp, MD1, Ronald Vender, MD, FRCPC2, Laura Park-Wyllie, MSc, PhD3, Timothy C. Disher, BSc, PhD4, Becky Hooper, MSc5, Nastaran Abbarin, MASc, PhD6, Rachel Teneralli, MS, PhD3, Richard Langley, MD, FRCPC7, Amanda M. Griffin, MSc8
  1Probity Medical Research, Waterloo, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3Johnson & Johnson (Canada), Markham, ON, Canada, 4Sandpiper Analytics, Halifax, NS, Canada, 5CRG-EVERSANA, Burlington, ON, Canada, 6Novartis, Toronto, ON, Canada, 7Dalhousie University, Halifax, NS, Canada, 8EVERSANA, Manager, HEOR, Halifax, NS, Canada

• MSR3: Parametric Model Selection: Beyond AIC/BIC in Health Economic Context
  Authors: Beatrice Suero1, Roya Gavanji, MSc2
  1EVERSANA, Associate Director, HEOR, Oakville, ON, Canada, 2EVERSANA, Burlington, ON, Canada 

• NMCP Delayed Time to Hospital Encounter and Reduced Cost compared to OMCP in Patients with Gastroparesis – A Real World Study
  Authors: Ramaa Nathan, PhD, Christopher Quesenberry, BS, Pierantonio Russo, MD, FCPP, FAAP, STS, Daniel Pfeffer, PhD, Mostafa Shokoohi, PhD
  EVERSANA Life Sciences, Overland Park, KS, USA 

Wednesday, May 14 – Poster Session 2 

• MSR53: Development and Validation of an LLM-Based Study Selection Tool for Automating Systematic Literature Reviews: Achieving Time Efficiency and Maintaining Gold Standard Accuracy
  Author(s): Christopher Olsen, BHSc, Jayson Brian Habib, MPH, Niki Srikanth, BSc, Kevin Hou, PhD, Nicole Ferko, MSc
  Value & Evidence Division, EVERSANA, Burlington, ON, Canada 

• MSR36: Methods for Handling Non-Proportional Hazards in Economic Modeling
  Author(s): Beatrice Suero¹, Roya Gavanji, MSc^{2
  1}EVERSANA, Associate Director, HEOR, Oakville, ON, Canada,²EVERSANA, Burlington, ON, Canada 

• SA26: Economic Burden of Hairy Cell Leukemia: A Systematic Review
  Author(s): Paridhi Gupta, BDS, MPH¹, Imtiaz Samjoo, BSc, MSc, PhD^{2
  1}EVERSANA, Pune, India,²EVERSANA, Burlington, ON, Canada 

 Thursday, May 15 – Poster Session 3 

•  SA47: Use of an Independent Data Review Committee to Promote Best Practices for External Control Arms: A Case Study in Relapsed/Refractory Multiple Myeloma
  Author(s):Uwe Siebert, MD, MPH, MSc, ScD¹, M. Alan Brookhart, PhD², Xavier Leleu, MD, PhD³, Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD⁴, Soko Setoguchi, MD, DrPH⁵, Nicolle Bonar, PhD⁶, Michael West, MSc⁶, Di Wang, MSc⁶, Mostafa Shokoohi, PhD⁶, Paul Spin, PhD⁶, Christian Hampp, PhD⁷, James Harnett, PharmD, MS⁷, Jeannette Green, MSc⁷, Olivier Humblet, Sc.D.⁷, Alexander Breskin, PhD, MPH⁷, Qiufei Ma, PhD^{7
  1}UMIT TIROL-University for Health Sciences and Technology, Hall in Tirol, Austria, ²Duke University, Durham, NC, USA,³Hôpital La Mileterie, Poitiers, France, ⁴University College Hospital, London, United Kingdom, ⁵Rutgers University, New Brunswick, NJ, USA, ⁶Eversana, Burlington, ON, Canada, ⁷Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA 

• MSR88: Key Considerations in the Use of Large Language Models for Data Extraction in Health Economics and Outcomes Research
  Author(s): Elise Aronitz, MSc, Jayson Brian Habib, MPH, Christopher Olsen, BHSc, Kevin Hou, PhD, Nicole Ferko, MSc
  EVERSANA, Burlington, ON, Canada

• SA33: Inclusion of Caregiver Costs and Quality of Life in Cost Effectiveness Analyses of Treatments for Neurological Conditions: Review of HTA Guidance Documents and Appraisals
  Author(s): Erin Wong, PhD¹, Alicyia Walczyk Mooradally, PhD¹, Ashley Concessio, MBiotech², Laura Pastor, MSc¹, Sumeet Singh, MSc¹, Adam E. Haynes, MSc², Se Ryeong Jang, MPH^{3
  1}EVERSANA, Burlington, ON, Canada, ²Eisai Limited, Mississauga, ON, Canada,³Eisai Inc., Nutley, NJ, USA 

• MSR79: The Impact of Prior Choice for Between-Study Heterogeneity in Network Meta-Analysis on Model Conclusions
  Author(s): Jenna Ellis, MSc¹, Anja Haltner, MSc^{2
  1}EVERSANA, Burlington, ON, Canada, ²EVERSANA, New York, NY, USA 

Thursday, May 15 – Poster Session 4 

• SA65: Systematic Literature Review (SLR) of Disease Burden Related to First-Line (1L) Unresectable, Locally Advanced, or Metastatic Gastric Cancer (GC) and Gastroesophageal Junction (GEJ) Adenocarcinoma
  Author(s): Elizabeth Smyth, MD¹, Wenxi Tang, MS², Alexa Sibiga, BSc³, Vien Do, BMSc³, Samantha Craigie, MSc³, Lin Zhan, MSc^{2
  1}Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, ²BeiGene, USA, Emeryville, CA, USA,³EVERSANA, Burlington, ON, Canada 

• HTA63: Trends in Use of Cost-Minimization Analyses in CDA-AMC Reimbursement Submissions
  Author(s): Bao Ngoc Nguyen, MSc, Michaela Spence, MSc, Aidan Dineen, PhD
  EVERSANA, Value and Evidence, Burlington, ON, Canada

• MSR114: Exploring the Impact of Data Availability on Time-Course Model-Based Network Meta-Analysis
  Author(s): Becky Hooper, MSc, Sarah Walsh, MSc, Jenna Ellis, MSc
  EVERSANA, Burlington, ON, Canada 

Friday, May 16 – Poster Session 5 

• MT42: Bench Study Assessing the Impact of the Next Generation of Vitreoretinal-Cataract System on System Set-Up and Tear-Down Time for Vitreoretinal Surgery
  Author(s): Yuta Inoue, MBA, MSc¹, Mukesh Dhariwal, MPH, MD¹, Daniel Son, MBDC², Margaret H. Ainslie-Garcia, MSc^{2
  1}Alcon Vision LLC, Fort Worth, TX, USA, ²EVERSANA, Burlington, ON, Canada 

• SA79: Targeted Review and Gap Assessment for Refractory Metastatic Colorectal Cancer Without Liver Metastases
  Author(s):Christopher Drudge, PhD¹, Varun Bhardwaj, MBA¹, Deepika Thakur, PhD¹, Noh Jin Park, PhD², Michael Locker, MD², Shengsheng Yu, PhD^{2
  1}Eversana, Burlington, ON, Canada, ²Exelixis, Inc., Alameda, CA, USA 

• HPR153: The Reimbursement Status of Ustekinumab Across HTAs: A Global Perspective
  Author(s): Kunal Shastri, MSc¹, Kerise Clarke, MSc², Bo Ren Long, MsC², Margaret H. Ainslie-Garcia, MSc^{2
  1}Fresenius Kabi SwissBioSim GmbH, Eysins, Switzerland, ²EVERSANA, Burlington, ON, Canada 

• EE488: The Economic Benefit of Biosimilars in North America: A Targeted Literature Review
  Author(s): Kunal Shastri, MSc¹, Kerise Clarke, MSc², Margaret H. Ainslie-Garcia, MSc^{2
  1}Fresenius Kabi SwissBioSim GmbH, Eysins, Switzerland, ²EVERSANA, Burlington, ON, Canada 

EVERSANA’s 2025 Oral Presentation

Thursday, May 15 | 10:15 AM – 11:15 AM 

• P28: The Use of Artificial Intelligence in the Development of Economic Models
  Author(s): Michaela Spence, MSc1, Belal Howidi, MSc1, Yixie Zhang, PhD1, Keith R. Kallmes, BSc², Aidan Dineen, PhD^{1
  1}EVERSANA, Value and Evidence, Burlington, ON, Canada, ²Nested Knowledge^®, Saint Paul, MN, USA